Research - Conatus Pharmaceuticals (CNAT) will release the combined results from 3 phase 1 and 2 studies on Thursday after the bell. CNAT is up 60% from our suggestion to get long the stock this Fall at $6.00.
Premium: Read NowResearch - By Zack Fink and guest contributor Dan Marks Bluebird bio (BLUE) will release data from the first Sickle Cell Disease patient treated with its LentiGlobin gene therapy … Continue Reading
Read NowResearch - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading
Premium: Read NowResearch - Our goal was to roll profit from this short-term trade into a small, longer-term position in SRNE, which we plan to let ride through TRIBECA.
Premium: Read NowResearch - Achillion Pharmaceuticals (ACHN) reported anticipated data for its nucleotide inhibitor ACH-3422 this morning alongside data from a phase 2 proxy study.
Premium: Read NowResearch - On Monday, Sorrento announced that Dr. Patrick Soon-Shiong made a $41 million investment in the company and now owns 19.9% of Sorrento.
Premium: Read NowResearch - With data for ONT-380 to be presented at SABCS, Oncothyreon (ONTY) announced it has licensed ONT-380 from partner Array Biopharma (ARRY) for $20 million.
Premium: Read Now
